The series A funding will help UMass-founded genetic disease therapy developer Apic Bio progress targeted drugs for ALS and Alpha-1 antitrypsin deficiency.

Apic Bio, a US-based genetic disease therapeutics spinout of University of Massachusetts Medical School (UMMS), closed a $40m series A round on Monday led by Morningside Venture Capital, the VC arm of investment firm Morningside Group.
The round included Alpha-1 Project, a profit-led subsidiary of Alpha-1 Foundation, as well as the ALS Investment Fund and A1ATD Investors.
Founded in 2017, Apic Bio is a genetic disease therapy developer focused on tackling amyotrophic lateral sclerosis (ALS), a disorder commonly…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?